Venus Medtech (Hangzhou) Inc.

SEHK:2500 주식 보고서

시가총액: HK$2.5b

Venus Medtech (Hangzhou) 미래 성장

Future 기준 확인 2/6

Venus Medtech (Hangzhou) (는) 각각 연간 85.9% 및 31.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 80.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -3.9% 로 예상됩니다.

주요 정보

85.9%

수익 성장률

80.6%

EPS 성장률

Medical Equipment 수익 성장39.2%
매출 성장률31.9%
향후 자기자본 수익률-3.9%
애널리스트 커버리지

Good

마지막 업데이트09 Jan 2024

최근 미래 성장 업데이트

Recent updates

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

May 29
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

May 11
What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07
Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12
Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04
Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28
We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09
Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01
Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16
We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12
A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05
Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07
Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14
What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29
Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29
Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08
Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

수익 및 매출 성장 예측

SEHK:2500 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261,707N/A285N/A4
12/31/20251,154-9-72416
12/31/2024809-289-327-2066
12/31/2023566-570-519-4226
6/30/2023452-1,208-839-797N/A
3/31/2023429-1,133-874-763N/A
12/31/2022406-1,058-908-729N/A
9/30/2022397-759-845-622N/A
6/30/2022387-461-781-515N/A
3/31/2022401-417-670-486N/A
12/31/2021416-374-559-457N/A
9/30/2021415-313-505-390N/A
6/30/2021413-252-452-322N/A
3/31/2021345-217-406-280N/A
12/31/2020276-182-361-237N/A
9/30/2020252-210-333-250N/A
6/30/2020228-238-305-264N/A
3/31/2020231-310-316-284N/A
12/31/2019233-381-328-303N/A
12/31/2018115-300-178-151N/A
12/31/201718-157-102-82N/A

애널리스트 미래 성장 예측

수입 대 저축률: 2500 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 2500 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 2500 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 2500 의 수익(연간 31.9% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 2500 의 수익(연간 31.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 2500 (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견